With inaugural fund, Pureos looks to build up Swiss biotech ecosystem

Nearly half of Pureos Bioventures’ first fund, which closed this week at $170 million, could be headed towards Swiss drug developers.

The firm began investing its global BB Pureos Bioventures LP fund last year. Pureos intends to spread its investments out across 15-20 therapeutics companies, with up to 40% headed toward Swiss biotechs...